Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0034065 (
pulmonary embolism
)
14,979
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Pasteau and Degrais in Paris used radium to treat prostatic cancer in 1907, radium was further used with different techniques including radium needles and radon seeds during twenty years. In 1951, Flock advocated colloidal radioactive gold with interesting palliative results. Permanent gold seeds implant was also used. But until 1970 with the appearance of Iodine 125 grain, brachytherapy was not widely employed. Hilaris and Whitmore treated almost 1000 cases until now, with few immediate complications. Survivals at 5 years are T1 96%, T2 76%, T3 69%. Conservation of potency and absence of late complications are the main benefits. However, the technique is a somewhat complex surgical procedure and the cases have to be carefully selected. Many others centers used iodine technique and Holm recently proposed an ingenious per-operative echography to improve the safety and accuracy of the permanent implantation. Removable implants with 192Ir wire (or nylon ribbon seeds) are obviously simpler and safer to implant through perineal route. For us, flexible plastic tubes is the technique of choice. In ten cases irradiated at 70 Gy level, no recurrences and no complications except one
pulmonary embolism
, but the patients were highly selected. For Syed rigid needles through perineal template is the technique of choice. External radiation is added after the implant, which delivered a dose of about 30 Gy. The results are satisfactory in the first 100 cases, but with a high level of complication. Comparative series and more follow-up are evidently requested, to know the exact place of brachytherapy in the treatment of
prostatic adenocarcinoma
.
...
PMID:[Cancer of the prostate: technics of curietherapy. Review of the literature and experience at the Institut Gustave-Roussy]. 409 8
Over a ten year period, 5,954 patients with benign prostatic hyperplasia (BPH) were hospitalized in our Institution. Of these, 1,000 cases were randomly chosen for the present study. Surgery was performed in 930 patients: transurethral resection (TUR) in 665 (72%) and open prostatectomy in 265 (28%). The pathological analyses revealed
prostatic adenocarcinoma
in 36 patients (4%). Seven patients were excluded: 5 due to a short follow-up (less than one year), one who had died from
pulmonary embolism
immediately postoperatively and one who had developed metastatic disease a few months after the operation. The age of the 29 evaluable patients ranged from 53 to 91 years (mean 72.7 years) and the overall mean follow-up was 43 months. Eighteen patients staged A1 were treated conservatively and followed from 12 to 127 months (mean 53.5 months). Two patients (11%) showed progression, one locally at 42 months (5.5%) and one developed bone metastasis at 15 months (5.5%) and died at 27 months (Mortality: 5.5%). Of the eleven patients with stage A2 prostatic cancer, 7 were managed conservatively (watchful waiting), 1 underwent radical prostatectomy and 3 received early hormone therapy for undifferentiated lesions. Five patients progressed (45%), including the three patients treated with early hormone therapy, 3 local (27%) and 2 systemic (18%). Two of the 11 patients died from cancer (18%) and 2 from unrelated causes. The Gleason grading system and tumor volume (focal or diffuse) were compared as prognostic factors using the Kaplan-Meyer and log-rank test.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:[Determination of prognostic factors in incidental prostatic carcinoma]. 751 66
A 73-year-old man presented to our hospital complaining of dysuria and nocturia. The examination revealed prostatic cancer. Metastatic cancer was not revealed by the examination. He underwent total prostatectomy and iliac lymphadenectomy. Pathological examination of the surgical specimen revealed moderately differentiated
adenocarcinoma of the prostate
with right iliac lymph node metastasis. On the 33rd postoperative day, he suddenly developed chest pain, dyspnea, tachycardia, and tachypnea. Arterial PO2 was 62 mmHg, and chest X-ray showed right ventricular hypertrophy. Pulmonary perfusion scan revealed multiple cold areas throughout both lung fields. The diagnosis was
pulmonary embolism
and anti-coagulant therapy was immediately successful in resolving his symptoms. We suggest that
pulmonary embolism
should be considered as one of the postoperative complications of urological operations.
...
PMID:[A case of pulmonary embolism following total prostatectomy]. 817 46
Adenocarcinoma of the prostate is occasionally associated with
pulmonary embolism
, occurring as a result of secondary hypercoagulable states or cancer-associated emboli. The objective of this study was to provide a review of clinical, histopathological and immunohistochemical features of poorly differentiated
prostatic adenocarcinoma
, emphasizing the relevance of undiagnosed malignancy as a cause of
pulmonary embolism
. The current study describes the case of a 78-year-old male who experienced remarkable clinical symptoms suggestive of
pulmonary embolism
. Following several diagnostic examinations, the patient was diagnosed with
pulmonary embolism
, which led to the detection of
prostatic adenocarcinoma
. Poorly differentiated adenocarcinoma with a Gleason's score of nine was set as a definite diagnosis. Multiple tumor emboli within small and medium-sized pulmonary blood vessels were found in all specimens taken from lung tissue. Immunohistochemical analysis showed diffuse and strong positivity of tumor cells within pulmonary arteries. Hidden malignancy is a diagnostic challenge that should be considered in the differential diagnosis of
pulmonary embolism
. Laboratory and radiological findings with additional histopathological evaluation are needed for the definite diagnosis.
...
PMID:An autopsy case of massive pulmonary tumor embolism due to undiagnosed prostatic adenocarcinoma. 3169 Oct 70